Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 876-884

  Bersani, Francesca ^a   Taulli, Riccardo ^a   Accornero, Paolo ^a   Morotti, Alessandro ^b   Miretti, Silvia ^a   Crepaldi, Tiziana ^a   Ponzetto, Carola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Bortezomib; Novel cancer therapies; Proteasome; Rhabdomyosarcoma

Indexed keywords

BORTEZOMIB; PROTEASOME;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUSE; MYOBLAST; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN INDUCTION; RHABDOMYOSARCOMA; THERAPY EFFECT; TRANSCRIPTION TERMINATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RHABDOMYOSARCOMA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 41849086234     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.022     Document Type: Article

References (29)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4 (2004) 349-360
2. Almond J.B., and Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16 (2002) 433-443
3. Crawford L.J., Walker B., Ovaa H., et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 66 (2006) 6379-6386
4. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2002) 3071-3076
5. Milano A., Iaffaioli R.V., and Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumors?. Eur J Cancer 43 (2007) 1125-1133
6. Merlino G., and Helman L.J. Rhabdomyosarcoma - working out the pathways. Oncogene 18 (1999) 5340-5348
7. Slater O., and Shipley J. Clinical relevance of molecular genetics to paediatric sarcomas. J Clin Pathol 60 (2007) 1187-1194
8. Wachtel M., Runge T., Leuschner I., et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24 (2006) 816-822
9. Kuttesch Jr. J.F. Multidrug resistance in pediatric oncology. Invest New Drugs 14 (1996) 55-67
10. Mugita N., Honda Y., Nakamura H., et al. The involvement of proteasome in myogenic differentiation of murine myocytes and human rhabdomyosarcoma cells. Int J Mol Med 3 (1999) 127-137
11. Blaney S.M., Bernstein M., Neville K., et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 22 (2004) 4804-4809
12. Muller M., Morotti A., and Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 22 (2002) 1060-1072
13. Piva R., Gianferretti P., Ciucci A., Taulli R., Belardo G., and Santoro M.G. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood 105 (2005) 1750-1758
14. Amiri K.I., Horton L.W., LaFleur B.J., Sosman J.A., and Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64 (2004) 4912-4918
15. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9 (2003) 789-795
16. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., and Sherman M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 273 (1998) 6373-6379
17. Ganjavi H., Gee M., Narendran A., Freedman M.H., and Malkin D. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 12 (2005) 397-406
18. Petitjean A., Mathe E., Kato S., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 (2007) 622-629
19. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002) 301-310
20. Wachtel M., Dettling M., Koscielniak E., et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64 (2004) 5539-5545
21. Maki R.G., Kraft A.S., Scheu K., et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103 (2005) 1431-1438
22. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
23. Yin D., Zhou H., Kumagai T., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24 (2005) 344-354
24. Ling Y.H., Liebes L., Jiang J.D., et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9 (2003) 1145-1154
25. Hideshima T., Chauhan D., Ishitsuka K., et al. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 24 (2005) 3121-3129
26. Sors A., Jean-Louis F., Pellet C., et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107 (2006) 2354-2363
27. Diller L., Sexsmith E., Gottlieb A., Li F.P., and Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95 (1995) 1606-1611
28. Nawrocki S.T., Bruns C.J., Harbison M.T., et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1 (2002) 1243-1253
29. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., and McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2 (2003) 835-843